Monday, November 23, 2020 8:38:15 AM
Mon, November 23, 2020, 8:30 AM EST
SAN JOSE, Calif., Nov. 23, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
This vaccine technology was invented by a research team from Cleveland Clinic, led by Dr. Vincent Tuohy, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Anixa has a worldwide, exclusive license to this technology.
The technology takes advantage of self-proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein, alpha-lactalbumin, is expressed only in the mammary glands during lactation and then disappears once lactation ceases. Dr. Tuohy discovered that this protein is abnormally expressed again when a woman contracts breast cancer, especially Triple Negative Breast Cancer (TNBC), the most deadly form of this disease. Dr. Tuohy postulated that if women could be immunized against this protein after their childbearing years, the immune system could be trained to destroy cancer cells as they arise while ignoring normal cells that no longer express this protein, thus making it difficult for the cancer to gain critical mass. Early studies to test this theory demonstrated highly significant prevention of breast cancer in animal models.
The technology is being developed at Cleveland Clinic with funding from the U.S. Department of Defense. The funding is expected to enable completion of two Phase 1 clinical trials.
"This has the potential to be a paradigm-shifting clinical study," said Dr. Tuohy. "If our data demonstrate results similar to the pre-clinical studies, this vaccine could have a significant impact on breast cancer, the most common malignancy in women. Furthermore, the way we think about controlling breast cancer may completely change."
"We look forward to moving this novel technology into the clinical stage of development," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "If the data in humans is comparable to the data in animals, Dr. Tuohy's 'retired' protein hypothesis will usher in a new way to prevent breast cancer, as well as other types of tumors."
"This initial clinical trial will be with women who have been diagnosed with high-risk early stage TNBC and are receiving standard of care at Cleveland Clinic," said Dr. G. Thomas Budd, Department of Medical Oncology at the Taussig Cancer Center at Cleveland Clinic, and the Clinical Investigator who will be conducting the trial. "We look forward to commencing the Phase 1 clinical trial and evaluating these patients."
Recent ANIX News
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties • PR Newswire (US) • 03/14/2024 12:45:00 PM
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress • PR Newswire (US) • 03/11/2024 12:00:00 PM
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 02/12/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 09:15:32 PM
- Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference • PR Newswire (US) • 01/29/2024 01:50:00 PM
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 01/23/2024 12:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:08:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:16 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/16/2024 10:29:43 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:43:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/16/2024 09:30:49 PM
- Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 • PR Newswire (US) • 01/10/2024 02:00:00 PM
- Anixa Biosciences to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/14/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 11:01:47 AM
- Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 11:00:00 PM
- Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 09:05:00 PM
- Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 02:58:20 PM
- Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference • PR Newswire (US) • 10/31/2023 12:30:00 PM
- Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board • PR Newswire (US) • 10/23/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM